Pay in 4 interest-free payments of $5.28 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
& Taylor, L
What sets us apart is our holistic approach, attention to detail, and unwavering commitment to client experience
Triple agonists add glucagon receptor activation, which: Increases resting energy expenditure by 8% to 12% (Jall et al., Diabetes Care 2024) Promotes hepatic fat oxidation and reduces steatosis May offset some of the lean mass loss seen with GLP-1 monotherapy (early signal, not yet confirmed in long-term trials) The weight loss ceiling for retatrutide appears to be 24% to 26% based on phase 3 data, though long-term real-world outcomes are not yet available
CJC-1295 is a tetrasubstituted version of the peptide that is also modified by adding a drug affinity complex (DAC) component called N-epsilon-3-maleimidopropionamide, which appears to bind to plasma proteins and may improve CJC-1295 pharmacokinetics
